Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Clinical Data
Biotech
Phase 3 Scholar Rock trial hits SMA goal, sending stock up 327%
Investors went wild despite the higher dose falling short of the targeted efficacy and Scholar Rock making no mention of a key secondary goal.
Nick Paul Taylor
Oct 7, 2024 8:45am
Ultragenyx tweaks gene therapy dosing to dial up efficacy
Oct 4, 2024 8:46am
Cash-strapped Gritstone starts search for strategic alternatives
Oct 1, 2024 10:07am
Rivus posts data to back up muscle-sparing obesity drug claims
Sep 30, 2024 11:09am
Cereno's HDAC inhibitor reduces risks from PAH in phase 2 trial
Sep 30, 2024 9:35am
Enanta's RSV antiviral crushes viral load in challenge study
Sep 26, 2024 7:43am
